Amgens Motesanib demonstrates efficacy in Thyroid Cancer

Phase II data published in the NEJM show Amgen’s Motesanib (AMG706) to induce partial responses in patients with advanced or metastatic differentiated thyroid cancer

Avastin significantly improves survival in metastatic colorectal cancer

Phase III data presented at the World Congress on Gastrointestinal Cancer show Avastin significantly improves survival in patients with metastatic colorectal cancer irrespective of K-Ras gene mutations

Novartis ALK inhibitor TAE684 effective in some EML4-ALK NSCLC cell lines

Administration of ALK inhibitor TAE684 inhibited the growth of H3122 EML4-ALK containing NSCLC cell lines. Activity was not observed in the DFCI032 cell line due to coactivation of EGFR/Erb2.

Coadministration of CDK inhibitor seliciclib with EGFR inhibitors increases activity

Studies published by Cyclacel on the coadministration of CDK inhibitor seliciclib with EGFR/HER2 inhibitors erlotinib, trastuzumab and AG1478 show that the drug combinations were significantly more active than any agent admnistered alone.

Coadministration of AZD0530 and Gefitinib increases growth inhibition in vitro

In vitro studies with Src inhibitor AZD0530 and EGFR kinase inhibitor Geftinib show that treatment with both drugs resulted in greater inhibition of head and neck squamous cell carcinoma cell growth and invasion compared with either agent alone.

Kissei publish data on new pyrimidine Syk inhibitors

Kissei have published a new series of pyrimidine Syk inhibitors in Bioorganic & Medicinal Chemistry